Corticotropin releasing factor receptor antagonists

  • US 10,849,908 B2
  • Filed: 04/18/2019
  • Issued: 12/01/2020
  • Est. Priority Date: 08/14/2017
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating congenital adrenal hyperplasia (CAH) in a human comprising administering to the human a therapeutically-effective amount of a CRF1 receptor antagonist or a pharmaceutically acceptable salt thereof, wherein an adrenocorticotropic hormone (ACTH) level in the human is reduced by at least 10% from baseline.

View all claims

    Thank you for your feedback